We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.15 | 0.93% | 124.20 | 124.64 | 121.78 | 122.04 | 3,636,593 | 01:00:00 |
From Nov 2023 to May 2024
By Elena Vardon
Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for its blockbuster obesity and diabetes treatments.
The Danish company, which makes the Wegovy obesity drug and diabetes drug Ozempic, said Thursday that the expansion of its facility in Chartres, southwest of Paris, will more than double the size of the site and is expected to create more than 500 new jobs. Construction, which has already started and will employ up to 2,000 external workers, is set to complete between 2026 and 2028, it said.
The site was set up in 1961 and currently employs around 1,600 people, Novo Nordisk said.
The group said earlier this month that it will invest more than $6 billion to boost production capacity, most of which will be dedicated to manufacturing active pharmaceutical ingredients used to treat diabetes and obesity.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
November 23, 2023 13:41 ET (18:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
